Natural Vascular Scaffold (NVS) Therapy for Treatment of Atherosclerotic Lesions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04188262|
Recruitment Status : Recruiting
First Posted : December 5, 2019
Last Update Posted : February 26, 2020
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Arterial Disease Peripheral Vascular Diseases Catheterization, Peripheral||Combination Product: NVS Therapy||Phase 1|
This is a prospective, non-randomized, multi-center, open label Phase 1 study to assess the safety, pharmacokinetics (PK), and preliminary efficacy trends to applying NVS therapy to de novo lesions in the superficial femoral artery (SFA) and the proximal popliteal artery (PPA) during percutaneous transluminal angioplasty (PTA) in patients with life-style limiting claudication due to obstructive SFA and proximal popliteal artery atherosclerosis. Each investigator will receive supervised training for each procedure.
Eligibility to participate in the study is determined during the screening period and prior to the index procedure with the NVS therapy. Study Data will be analyzed through the Day 365 follow-up visit.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease|
|Masking:||None (Open Label)|
|Official Title:||Natural Vascular Scaffolding (NVS) Therapy for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)|
|Estimated Study Start Date :||February 2020|
|Estimated Primary Completion Date :||August 2021|
|Estimated Study Completion Date :||August 2021|
Experimental: NVS Therapy
NVS Therapy will be delivered to de novo lesions in Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
Combination Product: NVS Therapy
Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS light Fiber, and NVS light source.
Other Name: Natural Vascular Scaffold
- Freedom from all-cause mortality, freedom from target limb major amputation, freedom from target lesion revascularization (TLR). [ Time Frame: Day 30 ]The overall composite occurrence of participants free from all-cause mortality, target limb major amputation, target lesion revascularization (TLR) through post-index procedure Day 30 will be summarized as a percentage.
- NVS Drug Plasma Concentrations [ Time Frame: Day 1 - 24 (Or Discharge) ]The Peak Plasma Concentration (Cmax) will be determined from plasma 10-8-10 Dimer concentrations for blood samples collected.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04188262
|Contact: Lasmy Tea, MS, MPHfirstname.lastname@example.org|
|Contact: Henry Hauseremail@example.com|
|United States, Louisiana|
|Cardiovascular Institute of the South||Recruiting|
|Houma, Louisiana, United States, 70360|
|Contact: Deanna Benoit 985-873-5613 Deanna.Benoit@cardio.com|
|Contact: Stacy Montero 985-873-5040 Stacey.Montero@cardio.com|
|Principal Investigator: Craig Walker, MD|
|United States, Tennessee|
|Wellmont CVA Heart Institute||Recruiting|
|Kingsport, Tennessee, United States, 37660|
|Contact: Lisa Vines 423-230-5640 Lisa.Vines@balladhealth.org|
|Contact: Terri Walker 423-230-5643 firstname.lastname@example.org|
|Principal Investigator: Christopher Metzger, MD|
|Study Director:||Henry Hauser||Alucent Biomedical|